180 Wealth Advisors LLC Lowers Holdings in Medtronic PLC $MDT

Key Points

• 180 Wealth Advisors cut its Medtronic stake by 75% in the second quarter, selling 29,822 shares and retaining 9,951 shares valued at approximately $778,000. Institutional investors collectively own 82.06% of the company.
• Medtronic reported quarterly revenue of $9.81 billion and adjusted EPS of $1.55, beating analyst expectations, while revenue rose 9.9% year over year. The company also raised its quarterly dividend to $0.72 per share, representing a 3.4% annualized yield.
• Analysts maintain a generally positive view, with a “Moderate Buy” consensus rating and an average price target of $98.83 versus a recent share price of $85.92. However, the company faces litigation risk after a jury ordered it to pay $88 million in a hernia-mesh case.

180 Wealth Advisors LLC decreased its holdings in shares of Medtronic PLC (NYSE:MDT - Free Report) by 75.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 9,951 shares of the medical technology company's stock after selling 29,822 shares during the quarter. 180 Wealth Advisors LLC's holdings in Medtronic were worth $778,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in MDT. Monetary Solutions Ltd purchased a new position in shares of Medtronic during the 4th quarter worth $27,000. Anfield Capital Management LLC increased its position in shares of Medtronic by 410.7% during the 4th quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company's stock worth $27,000 after purchasing an additional 230 shares during the last quarter. Acumen Wealth Advisors LLC purchased a new stake in Medtronic in the 4th quarter valued at about $29,000. Imprint Wealth LLC purchased a new stake in Medtronic in the 3rd quarter valued at about $31,000. Finally, Basepoint Wealth LLC purchased a new stake in Medtronic in the 4th quarter valued at about $32,000. Hedge funds and other institutional investors own 82.06% of the company's stock.

Medtronic Stock Down 0.1%

Shares of NYSE:MDT opened at $85.92 on Friday. The firm has a market capitalization of $109.98 billion, a PE ratio of 23.03, a price-to-earnings-growth ratio of 2.31 and a beta of 0.55. Medtronic PLC has a 1 year low of $73.31 and a 1 year high of $106.33. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.13 and a quick ratio of 1.62. The firm's 50-day moving average is $81.68 and its two-hundred day moving average is $86.68.

Medtronic (NYSE:MDT - Get Free Report) last announced its quarterly earnings data on Wednesday, June 3rd. The medical technology company reported $1.55 earnings per share for the quarter, beating analysts' consensus estimates of $1.54 by $0.01. Medtronic had a net margin of 13.20% and a return on equity of 14.51%. The firm had revenue of $9.81 billion during the quarter, compared to analysts' expectations of $9.62 billion. During the same quarter in the previous year, the business posted $1.62 earnings per share. The business's quarterly revenue was up 9.9% compared to the same quarter last year. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. Analysts predict that Medtronic PLC will post 5.94 EPS for the current year.

Medtronic Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, July 17th. Stockholders of record on Friday, June 26th were given a dividend of $0.72 per share. This is an increase from Medtronic's previous quarterly dividend of $0.71. This represents a $2.88 dividend on an annualized basis and a dividend yield of 3.4%. The ex-dividend date of this dividend was Friday, June 26th. Medtronic's dividend payout ratio is currently 77.21%.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. The Goldman Sachs Group lowered their target price on shares of Medtronic from $84.00 to $83.00 and set a "neutral" rating for the company in a research note on Thursday, June 4th. Mizuho reduced their price target on shares of Medtronic from $120.00 to $100.00 and set an "outperform" rating on the stock in a research note on Wednesday, June 3rd. Needham & Company LLC restated a "buy" rating and issued a $101.00 price objective on shares of Medtronic in a report on Wednesday, June 17th. BTIG Research reaffirmed a "buy" rating and set a $91.00 price objective on shares of Medtronic in a research report on Monday, July 13th. Finally, JPMorgan Chase & Co. dropped their target price on shares of Medtronic from $100.00 to $86.00 and set a "neutral" rating for the company in a report on Thursday, June 4th. Eighteen research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $98.83.

Medtronic News Roundup

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic received an expanded CE Mark indication in Europe for its Affera™ Mapping and Ablation System and Sphere-9™ Catheter to treat ventricular arrhythmias, including ventricular tachycardia and premature ventricular complexes. The approval expands the addressable market for the company’s cardiac-ablation technology and supports its international growth strategy. U.S. pivotal-trial enrollment is also underway. Medtronic announces expanded CE Mark indication for Affera and Sphere-9
• Positive Sentiment: A bullish investment opinion argues that Medtronic’s medical-device portfolio and long-term growth prospects could support substantial appreciation through the end of 2026. This is an analyst-style opinion rather than a new company announcement, so its effect is likely limited. Medtronic could soar by 40 percent
• Neutral Sentiment: Medtronic recently exceeded quarterly revenue and adjusted-EPS expectations, reporting $9.81 billion in revenue and $1.55 in EPS. Revenue increased 9.9% year over year, while full-year fiscal 2027 EPS guidance remains $5.90 to $6.00. These results provide a constructive operating backdrop but do not eliminate litigation concerns.
• Negative Sentiment: A U.S. jury ordered Medtronic to pay $88 million in the first trial involving allegations related to Covidien hernia mesh. Although the award may be manageable relative to Medtronic’s size, the verdict could raise concerns about additional lawsuits, settlement costs and potential reputational damage. Jury says Medtronic owes 88 million dollars in hernia mesh case

Insider Buying and Selling at Medtronic

In other news, EVP Harry Skip Kiil sold 4,189 shares of the stock in a transaction on Monday, June 8th. The stock was sold at an average price of $80.44, for a total value of $336,963.16. Following the sale, the executive vice president directly owned 37,227 shares in the company, valued at approximately $2,994,539.88. This trade represents a 10.11% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.26% of the company's stock.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic's offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source